Thursday, December 9, 2010
Bavarian Nordic AS, of Kvistgard, Denmark, reached a special protocol assessment agreement with the FDA for a Phase III registration study of Prostvac, an off-the-shelf therapeutic vaccine being developed under a cooperative research and development agreement with the National Cancer Institute, in patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.